Nimbus Biotechnology is presenting innovative tools for plasma protein binding on the Drug Discovery Technology 2006 at Boston, USA
Besides its Transil Adme assays for human and rat serum albumin the company is now launching an service assay for alpha-acid glycoprotein (AGP).
One of the most important questions in drug discovery is the free fraction of a compound in the blood of an organism.
As an acute phase protein, AGP's serum concentration increases in response to systemic tissue injury, inflammation or infection.
Even stress, race and ethnicity have an influence on the serum concentration.
Therefore whole plasma samples may not be an appropriate way especially for AGP binders.
The combination of HSA and AGP binding, both easy to measure with the well known Transil technology, should be a reliable method to estimate the binding of a compound to whole serum.
Other highlights to be discovered at the booth of Nimbus Biotechnology are their projects on the prediction of plasma/brain partition for safety issues or for the development of CNS active drugs and on a homogenous method for permeation measurements.
